Literature DB >> 11252008

Sample size tables for exact single-stage phase II designs.

R P A'Hern1.   

Abstract

Tables for single-phase II trials based on the exact binomial distribution are presented. These are preferable to those generated using Fleming's design, which are based on the normal approximation and can give rise to anomalous results. For example, if the upper success rate is accepted, the lower success rate, which the trial is designed to reject, may be included in the final confidence interval for the proportion being estimated. Copyright 2001 John Wiley & Sons, Ltd.

Mesh：

Substances：

Year:  2001        PMID： 11252008     DOI： 10.1002/sim.721

Source DB:  PubMed          Journal:  Stat Med        ISSN： 0277-6715            Impact factor:   2.373


  112 in total

1.  The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma.

Authors:  Antonio Curti; Roberto M Lemoli; Giulia Tolomelli; Katia Mancuso; Paola Tacchetti; Francesca Patriarca; Monica Galli; Lucia Pantani; Beatrice Zannetti; Maria Rosa Motta; Simonetta Rizzi; Elisa Dan; Barbara Sinigaglia; Valeria Giudice; Andrea Olmo; Mario Arpinati; Gabriella Chirumbolo; Renato Fanin; Russell E Lewis; Laura Paris; Francesca Bonifazi; Michele Cavo
Journal:  Bone Marrow Transplant       Date:  2019-11-25       Impact factor: 5.483

2.  Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant.

Authors:  Robert J Lechleider; Philip M Arlen; Kwong-Yok Tsang; Seth M Steinberg; Junko Yokokawa; Vittore Cereda; Kevin Camphausen; Jeffrey Schlom; William L Dahut; James L Gulley
Journal:  Clin Cancer Res       Date:  2008-08-15       Impact factor: 12.531

Review 3.  The promise of futility trials in neurological diseases.

Authors:  Marcus W Koch; Lawrence Korngut; David G Patry; Yahya Agha-Khani; Christopher White; Justyna R Sarna; Michael Yeung; V Wee Yong; Daniel Y C Heng; Gary Cutter; Luanne Metz
Journal:  Nat Rev Neurol       Date:  2015-03-17       Impact factor: 42.937

4.  Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas.

Authors:  Stéphane Goutagny; Eric Raymond; Marina Esposito-Farese; Stéphanie Trunet; Christian Mawrin; Daniele Bernardeschi; Béatrice Larroque; Olivier Sterkers; Marco Giovannini; Michel Kalamarides
Journal:  J Neurooncol       Date:  2015-01-08       Impact factor: 4.130

5.  Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study.

Authors:  Alessandra Fabi; Giulio Metro; Antonello Vidiri; Gaetano Lanzetta; Mariantonia Carosi; Stefano Telera; Marta Maschio; Michelangelo Russillo; Isabella Sperduti; Carmine M Carapella; Francesco Cognetti; Andrea Pace
Journal:  J Neurooncol       Date:  2010-03-30       Impact factor: 4.130

6.  Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study.

Authors:  Neal D Shore; Stephen A Boorjian; Daniel J Canter; Kenneth Ogan; Lawrence I Karsh; Tracy M Downs; Leonard G Gomella; Ashish M Kamat; Yair Lotan; Robert S Svatek; Trinity J Bivalacqua; Robert L Grubb; Tracey L Krupski; Seth P Lerner; Michael E Woods; Brant A Inman; Matthew I Milowsky; Alan Boyd; F Peter Treasure; Gillian Gregory; David G Sawutz; Seppo Yla-Herttuala; Nigel R Parker; Colin P N Dinney
Journal:  J Clin Oncol       Date:  2017-08-23       Impact factor: 44.544

7.  Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer.

Authors:  Charles M Rudin; Julie R Brahmer; Rosalyn A Juergens; Christine L Hann; David S Ettinger; Rosa Sebree; Ruth Smith; Blake T Aftab; Peng Huang; Jun O Liu
Journal:  J Thorac Oncol       Date:  2013-05       Impact factor: 15.609

8.  Smaller sample sizes for phase II trials based on exact tests with actual error rates by trading-off their nominal levels of significance and power.

Authors:  I Khan; S-J Sarker; A Hackshaw
Journal:  Br J Cancer       Date:  2012-11-20       Impact factor: 7.640

9.  Hepatic arterial infusion with oxaliplatin and 5-FU/folinic acid for advanced biliary tract cancer: a phase II study.

Authors:  M Sinn; A Nicolaou; B Gebauer; P Podrabsky; D Seehofer; J Ricke; B Dörken; H Riess; B Hildebrandt
Journal:  Dig Dis Sci       Date:  2013-03-24       Impact factor: 3.199

10.  Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases.

Authors:  M Cosimelli; R Golfieri; P P Cagol; L Carpanese; R Sciuto; C L Maini; R Mancini; I Sperduti; G Pizzi; M G Diodoro; M Perrone; E Giampalma; B Angelelli; F Fiore; S Lastoria; S Bacchetti; D Gasperini; O Geatti; F Izzo
Journal:  Br J Cancer       Date:  2010-07-13       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.